Search

El presente trabajo investigativo tuvo por objetivo, determinar la relación que existe entre el aula virtual y formación profesional tecnológica en tiempos de pandemia de los estudiantes de formación docente de una universidad pública. Fue de enfoque cuantitativo, tipo básica y descriptivo-correlacional, con diseño no experimental-transversal y con método hipotético-deductivo. Investigación desarrollada en estudiantes de 4 escuelas profesionales del VIII ciclo universitario que están desarrollando sus asignaturas de formación tecnológica en la modalidad virtual, con una muestra proporcional estratificada por departamentos académicos, y se determinó una muestra de 57 estudiantes entre varones y mujeres, se elaboró dos cuestionarios de 30 ítems cada uno para la recolección de datos para cada variable, con escala de tipo Likert con 4 alternativas de respuesta. La validez y confiabilidad de los instrumentos, así como el tratamiento estadístico, fueron procesados con el paquete estadístico SPSS V-25. Se determinó que existe una relación positiva alta entre las variables de estudio (p < 0,05, correlación Rho de Spearman= 0,947 ** siendo una correlación positiva alta).

El presente trabajo investigativo tuvo por objetivo determinar la relación que existe entre la cultura investigativa y la elaboración de trabajos de grado de los estudiantes de formación docente de una universidad pública. De enfoque cuantitativo, de tipo básica y descriptivo-correlacional, con diseño no experimental- transversal y con método hipotético-deductivo. Investigación desarrollada en estudiantes de 4 escuelas profesionales del IX ciclo universitario que han desarrollado los cursos de talleres de investigación, con una muestra proporcional estratificada por departamentos académicos y se determinó una muestra de 73 estudiantes entre varones y mujeres, se elaboró dos cuestionarios de 30 ítems cada uno para la recolección de datos para cada variable, con escala de tipo Likert con 4 alternativas de respuesta. La validez y confiabilidad de los instrumentos, así como el tratamiento estadístico, fueron procesados con el paquete estadístico SPSS V-24. Las conclusiones a que se arribó fue que existe una relación positiva alta entre las variables de estudio (p < 0,05, correlación Rho de Spearman = 0,755**, siendo una correlación positiva alta).

Treating an anticoagulated patient with vitamin K antagonists (VKA) remains a challenge, especially in areas where dicoumarins are still the first drug of choice due to the cost of other oral anticoagulants. Anticoagulation clinics have proven to be the most efficient and safe way to avoid thrombotic and hemorrhagic complications and to keep patients in optimal treatment range. However, they require adequate infrastructure and trained personnel to work properly. In this Argentine consensus we propose a series of guidelines for the effective management of the anticoagulation clinics. The goal is to achieve the excellence in both the clinical healthcare and the hemostasis laboratory for the anticoagulated patient. The criteria developed in the document were agreed upon by a large group of expert specialists in hematology and biochemistry from all over the country. The criteria presented here must always be considered when indicating VKA although they had to be adapted to the unequal reality of each center. Taking these premises into consideration will allow us to optimize the management of the anticoagulated patient with VKA and thus minimize thrombotic and hemorrhagic intercurrences, in order to honor our promise not to harm the patient.El tratamiento de un paciente anticoagulado con antagonistas de la vitamina K (AVK) sigue siendo un desafío, especialmente en regiones donde, por el costo, los dicumarínicos son todavía la alternativa más buscada a la hora de elegir un anticoagulante oral. Las clínicas de anticoagulación han demostrado ser la forma más eficiente y segura de evitar complicaciones trombóticas y hemorrágicas y de mantener al paciente en rango óptimo de tratamiento. Sin embargo, requieren de una adecuada infraestructura y personal capacitado para que funcionen eficientemente. En este consenso argentino se propone una serie de parámetros para la gestión efectiva de una clínica de anticoagulación. El objetivo es lograr una elevada calidad desde el punto de vista clínico-asistencial a través de un laboratorio de hemostasia de excelencia. Los criterios desarrollados en el documento fueron consensuados por un amplio grupo de expertos especialistas en hematología y en bioquímica de todo el país. Estos criterios deben adaptarse a la irregular disponibilidad de recursos de cada centro, pero siempre se los debe tener en cuenta a la hora de indicar el tratamiento anticoagulante con estas drogas. Tener en consideración estas premisas nos permitirá optimizar la atención del enfermo anticoagulado con AVK y de esta forma minimizar las intercurrencias trombóticas y hemorrágicas a las que está expuesto, para así honrar nuestra promesa de no dañar al paciente.

La innovación permite anticipar nuevas oportunidades a las organizaciones, beneficiando la solución creativa de problemas, utilizando estrategias que garanticen flexibilidad en condiciones cambiantes. En este sentido, la investigación pretende realizar un estudio documental, el cual persigue abordar teóricamente la innovación como elemento fundamental para el éxito en las organizaciones. Para ello se estudiaran conceptos presentados por autores como: Schumpeter (1939), Drucker (1985), Mandado, Fernández y Dorio (2003), Escorsa y Valls (2003),entre otros. La investigación es descriptiva, no experimental, en la cual se consideran realidades teóricas del objeto de estudio, con un análisis sistémico y organizado. La innovación se presenta como una oportunidad para mejorar y promover estrategias que estimulen a desarrollar una visión integral en la organización, que contribuirán al desarrollo de ventajas competitivas que garanticen el éxito en las organizaciones. La innovación puede desempeñar un papel estratégico en las organizaciones, que puede ser útil en la medida que encuentre a los actores adecuados en su proceso de creación y difusión logrando el éxito en las empresas.

La eritropoyetina recombinante (rHuEPO) se ha transformado en la citoquina más utilizada terapéuticamente en el mundo. Luego del éxito obtenido en pacientes con insuficiencia renal terminal, se pudo establecer la utilidad de la terapia con rHuEPO para mejorar otras anemias, incluso en pacientes pediátricos y neonatos. El tratamiento o la prevención de la anemia del prematuro mediante el uso de rHuEPO llevó a una significativa reducción en cantidad de transfusiones y en exposición a dadores. Aún debe establecerse una clara definición sobre cuáles niños prematuros deben recibir tratamiento rutinariamente. Otras indicaciones en período neonatal incluyen anemias hiporregenerativas y hemolíticas. La eficacia de la rHuEPO en niños mayores, con excepción de la insuficiencia renal crónica, no ha sido tan exhaustivamente evaluada como en adultos. Mientras que durante los últimos años se han realizado gran cantidad de estudios en adultos con anemia asociada al cáncer o a infección por HIV, permitiendo establecer conclusiones claras sobre su eficacia, sólo escasa cantidad de estudios con pequeño número de pacientes han sido realizados en niños. Hasta la fecha, los resultados sugieren que la terapia con rHuEPO en niños es tan útil como en adultos, pero la realización de estudios aleatorizados prospectivos incluyendo gran número de pacientes es esencial para alcanzar conclusiones definitivas. Los resultados de estudios dirigidos a evaluar la eficacia de la rHuEpo para mantener una dosis adecuada de ribavirina en pacientes en tratamiento por hepatitis C son alentadores. La utilización potencial de los efectos no hemopoyéticos de la rHuEPO en neonatos es un terreno novedoso y apasionante. El rol de la Epo como citoprotector para sistema nervioso central y mucosa intestinal está bajo investigación exhaustiva.Recombinant human erythropoietin (rHuEpo) has become the most widely used cytokine in the world. Following the success of its use in patients with end-stage renal disease, the usefulness of rHuEpo to ameliorate other anemias was assessed, including pediatric patients and newborn infants. The treatment or prevention of anemia of prematurity with rHuEpo resulted in a significant reduction in the number of transfusions and donor exposure. A clear definition of which premature babies must receive therapy needs yet to be established. Other indications in neonatal period include hyporegenerative and hemolytic anemias. With the exception of chronic renal failure, in older children the efficacy of rHuEpo has not been evaluated as in adults. While an impressive amount of studies were carried out during the last years in adult patients with cancer-related or HIV-infection-related anemias, allowing to establish clear conclusions on its efficacy, only a few trials with small number of patients have been reported in children. Up to date, results in pediatric patients suggest that rHuEpo therapy is as useful as in adult patients, but prospective, randomized trials including large number of patients are essential to achieve definitive conclusions. Results of studies designed to evaluate the efficacy of rHuEpo for sustaining an adequate dose of ribavirin in patients receiving treatment for hepatitis C are encouraging. The potential for use of the non-hematopoietic effects of rHuEpo in newborn infants is a novel and exciting issue. The role of rHuEpo as a tissue protective factor for central nervous system and intestinal mucosa is under exhaustive investigation.

This paper assesses the current scenario of the Portuguese media for-profit journalism within a post-industrial changing context of news media system comprising new actors, practices, and platforms. Drawing on the daily and weekly national press over a 35 yearsperiod, it analyzes different criteria related to both the ownership structure and business models in order to assess the different factors that account for the sustainability of the press. The findings of a closer insight into the local distinctive reality of Portugal shows it is still possible for new ventures to succeed in a scenario of creative destruction. Such an unprecedented study on an underexplored polarised pluralist Southern European country, somewhat comparable to Latin and South American press systems, is revealing that new startups, owned by diversified business conglomerates, pop up even in a crisis situation scenario., Fundação para a Ciência e a Tecnologia (FCT)

Recombinant human erythropoietin (rHuEpo) has become the most widely used cytokine in the world. Following the success of its use in patients with end-stage renal disease, the usefulness of rHuEpo to ameliorate other anemias was assessed, including pediatric patients and newborn infants. The treatment or prevention of anemia of prematurity with rHuEpo resulted in a significant reduction in the number of transfusions and donor exposure. A clear definition of which premature babies must receive therapy needs yet to be established. Other indications in neonatal period include hyporegenerative and hemolytic anemias. With the exception of chronic renal failure, in older children the efficacy of rHuEpo has not been evaluated as in adults. While an impressive amount of studies were carried out during the last years in adult patients with cancer-related or HIV-infection-related anemias, allowing to establish clear conclusions on its efficacy, only a few trials with small number of patients have been reported in children. Up to date, results in pediatric patients suggest that rHuEpo therapy is as useful as in adult patients, but prospective, randomized trials including large number of patients are essential to achieve definitive conclusions. Results of studies designed to evaluate the efficacy of rHuEpo for sustaining an adequate dose of ribavirin in patients receiving treatment for hepatitis C are encouraging. The potential for use of the non-hematopoietic effects of rHuEpo in newborn infants is a novel and exciting issue. The role of rHuEpo as a tissue protective factor for central nervous system and intestinal mucosa is under exhaustive investigation.

Patients with stage I-II A non bulky Hodgkin’s lymphoma (HL) are successfully treated with 2–4 cycles of ABVD plus IF radiotherapy (RT). Although the negative impact in DFS and OS of B symptoms and bulky disease(X) is widely accepted, other risk factors such as number of lymph node regions involved or extensive spleen involvement have also been reported. What is the best treatment for such patients? Is radiotherapy necessary? We report here our experience with protocol HD 98 in 62 patients, with stage I–II HL. Since January 98 we have included 30 individuals without risk factors and 32 with one of the following risk factors: B symptoms (n:11), X (n:9), extensive spleen involvement (n:1) and involvement of more than two lymph node regions (n:11). Other patient characteristics were: age: x 31yrs (15–69), sex: females 31, males :31. Ann Arbor stage IA :11, IB :1, IIA: 36, IIB :14. Histologic subtypes were: LP: 4, NS: 42, MC: 15, lymphocyte rich :1. Patients with favourable features received 4 cycles of ABVD plus IFRT, those with unfavourable factors received 6–8 cycles of ABVD plus RT in areas of bulky or residual disease. Results: 59/61 evaluable patients obtained CR or CRu. Two patients were considered primary resistant. Three patients relapsed at 7, 13 and 30 months after completion of treatment. Autologus bone marrow transplant was performed in four patients. The two primary resistant patients relapsed after the transplant and died with proggressive disease. Those patients transplanted in a chemosensitive relapse are currently in CR. With a median follow up of 46m (13–84) 96.7% of the patients are alive, in CR. Conclusions: In our experience patients with unfavourable stages I–II HL are succesfully treated with 6–8 cycles of ABVD. In such patients RT might only be necessary in areas of bulky or residual disease.

In our series of consecutive patients (p) with objectively diagnosed VTE, cancer constitutes the most frequent ethiology (25%) followed by idiopathic (24%), clinical causes (22%), orthopedics and trauma (16%), general surgery (7%), obstetric entities (3%) and others (3%). Among the neoplastic subtypes, HM are the most prevalent ones followed by prostatic, colonic, lung and CNS cancers. A recent publication (Blom et al, JAMA2005; 293:715) shows this previously undisclosed high tendency of HM for provoking VTE. Our current study describes the experience with this association from 1996 to 2005, excluding central vein catheter thrombosis. Out of 531 p with VTE, 138 have cancer and 34 of them, HM, with the following distribution: plasma cells discrasias (PCD) 9 (4 on treatment with thalidomide), diffuse large cell lymphomas (DLCL) 8, indolent lymphomas (IL) 6, CLL 5, mantle cell lymphoma 1, Burkitt lymphoma 1, RAEB 1, AML 1, myelofibrosis 1, P vera 1. In 25/34 p, the HM was previously known at diagnosis of VTE and mostly active or on treatment. In the other 9 p, the clinical presentation was as an idiopathic VTE, and during follow-up the following HM were disclosed: PCD: 3, CLL: 2, DLCL: 1, IL: 1, myelofibrosis: 1, RAEB: 1. Table 1 Comments: PCD and DLCL constitute the two HM more frequently associated with VTE. However, the contribution of less agressive neoplasms such as indolent lymphomas and CLL is not negligible As in solid tumors, recurrences are high, specially when anticoagulated patients are off-therapy In spite of more chemotherapy related-thrombocytopenia and bone marrow involvement, bleeding rates do not differ of those observed in solid tumors Given the frequent association with VTE, and the probable heterogeneity in the thrombophilic potency of these different entities collectively grouped as HM, prospective multicentric studies are clearly needed to identify groups of patients with HM suitable for primary prophylaxis of VTE. Such studies should also be designed to provide further clue about the use of LMWH instead of oral anticoagulants for secondary prophylaxis in HM. Table 1. Main clinical findings in patients able to be evaluated during follow-up Events Hematologic Malignancies Solid Neoplasms Recurrences 6/28 (21.4%) 5 off anticoagulation 15/106 (14.1%) 7 off anticoagulation (p=ns) Major bleeding 2/28 (7.1%) 10/106 (9.4%) (p=ns)